Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 20, 2004 W.D. Crotty	$1 Billion Pharmion? The specialty drug company's stock soars on the FDA's approval of a drug that treats a blood condition.
The Motley Fool January 29, 2010 Brian Orelli	Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
The Motley Fool August 6, 2007 Brian Orelli	Hopeful Investors Stoke Pharmion's Price Clinical trials to get a drug approved for new uses usually don't have the gusto that trials for the original New Drug Application have, but Pharmion results released last week have blown the stock price through the roof.
The Motley Fool July 3, 2008 Brian Lawler	Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool December 27, 2007 Brian Lawler	A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
The Motley Fool October 23, 2009 Brian Orelli	Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool February 6, 2007 Brian Lawler	Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook.
The Motley Fool December 7, 2009 Brian Orelli	When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals.
The Motley Fool May 8, 2007 Brian Lawler	Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool December 8, 2009 Brian Orelli	Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.
The Motley Fool January 28, 2011 Brian Orelli	Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase.
The Motley Fool November 30, 2007 Brian Lawler	MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool April 30, 2010 Brian Orelli	New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene.
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
The Motley Fool October 30, 2006 Brian Lawler	Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note.
The Motley Fool October 30, 2006 Brian Lawler	Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note.
The Motley Fool January 30, 2009 Brian Orelli	Celgene's Double Take Still Looks Good No one is going to stop using Celgene's cancer-fighting products just because the economy is in the tank, so the company should have no problem hitting or even exceeding its growth estimates the way it has before.
The Motley Fool June 8, 2010 Rich Smith	This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool November 6, 2007 Brian Lawler	It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results.
The Motley Fool July 29, 2010 Brian Orelli	This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool April 30, 2007 Brian Lawler	The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool March 26, 2008 Brian Lawler	Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population.
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool January 8, 2007 Brian Lawler	Millennium Looks Ahead Shares of the biopharmaceutical company ended the year more than 10% higher, despite the presence of increased competition for its cancer treatment Velcade and all sorts of attempted merger and acquisition activity within the company. The pharmaceutical foresees a mixed 2007.
The Motley Fool October 6, 2010 Brian Orelli	Celgene Is All Grown Up An acquirer is on the prowl.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool December 11, 2007 Brian Lawler	The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion.
Chemistry World July 29, 2015 Phillip Broadwith	Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments.
The Motley Fool March 23, 2005 John Reeves	Stock Madness 2005: Lloyds TSB vs. Celgene Backgrounds on two stocks you might want to consider: Lloyds and Celgene.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool December 28, 2007 Brian Orelli	Investing in a Purchased Company Billionaire investor Steven Cohen, through his hedge fund SAC Capital Advisors, ups his stake in biotech company Pharmion. Let's take a look at why.
The Motley Fool June 30, 2010 Brian Orelli	Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term.
The Motley Fool September 26, 2006 Brian Lawler	GPC's Trial Glee A new platinum-based cancer treatment yields encouraging results. Investors, take note.
The Motley Fool March 21, 2005 Alyce Lomax	Stock Madness 2005: Dell vs. Celgene The computer maker and the biotech company vie for a berth in the next round of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool November 4, 2011 Luke Timmerman	Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement.
Chemistry World July 2, 2013 Sonja Hampel	Thalidomide teams-up with turmeric to kill myeloma cells Cancer researchers in the US and China have combined the turmeric spice pigment curcumin and the drug thalidomide to create hybrid compounds that can kill multiple myeloma cells.